CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 126 enrolled
Drug / intervention
JNJ-68284528biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03548207
NCT03548207Phase 2Completed
CompareCT.gov

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC·interventional·Posted Jun 7, 2018·Updated Jul 30, 2025

In Brief

A Phase 2 clinical trial evaluating JNJ-68284528 for Multiple Myeloma. Completed, enrolled 126 participants across 21 sites in 2 countries.

Detailed Summary

The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 7, 2018
Enrollment StartJun 29, 2018
Primary CompletionAug 23, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.1 years ago

Interventions

JNJ-68284528biological

JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).